Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment

被引:144
作者
Crawford, BAL [1 ]
Liu, PY
Kean, MT
Bleasel, JF
Handelsman, DJ
机构
[1] Royal Prince Alfred Hosp, Dept Endocrinol, Camperdown, NSW 2050, Australia
[2] Royal Prince Alfred Hosp, ANZAC Res Inst, Camperdown, NSW 2050, Australia
[3] Royal Prince Alfred Hosp, Dept Androl, Camperdown, NSW 2050, Australia
[4] Royal Prince Alfred Hosp, Inst Rheumatol & Orthopaed, Camperdown, NSW 2050, Australia
[5] Concord Hosp, Sydney, NSW, Australia
[6] Univ Sydney, Sydney, NSW 2006, Australia
关键词
D O I
10.1210/jc.2002-021827
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Long-term glucocorticoid therapy in men is associated with loss of bone and muscle mass as well as a decrease in serum testosterone. We tested the effect of two androgens, testosterone and its minimally aromatizable analog nandrolone, on muscle mass (dual x-ray absorptiometry), muscle strength (knee flexion and extension by isokinetic dynamometry), bone mineral density (BMD), and quality of life (Qualeffo-41 questionnaire) in 51 men on a mean daily prednisone dose of 12.6 +/- 2.2 mg. Men were randomized, double blind, to testosterone (200 mg mixed esters), nandrolone decanoate (200 mg), or placebo given every fortnight by im injection for 12 months. At 12 months, both androgens increased muscle mass (mean change from baseline +3.5%, +5.8%, and -0.9% in testosterone, nandrolone, and placebo groups, respectively, P < 0.0001) and muscle strength (P < 0.05). Lumbar spine BMD increased significantly only in men treated with testosterone (4.7 +/- 1.1%, P < 0.01). There was no significant change in hip or total body BMD. Testosterone, but not nandrolone or placebo, improved overall quality of life (P < 0.001). These results suggest that androgen therapy may have a role in ameliorating adverse effects of glucocorticoid therapy such as muscle and bone loss and aromatization is necessary for androgen action on bone but not on muscle.
引用
收藏
页码:3167 / 3176
页数:10
相关论文
共 68 条
[1]   Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis [J].
Adachi, JD ;
Bensen, WG ;
Brown, J ;
Hanley, D ;
Hodsman, A ;
Josse, R ;
Kendler, DL ;
Lentle, B ;
Olszynski, W ;
SteMarie, LG ;
Tenenhouse, A ;
Chines, AA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) :382-387
[2]   STEROID-INDUCED FRACTURES AND BONE LOSS IN PATIENTS WITH ASTHMA [J].
ADINOFF, AD ;
HOLLISTER, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (05) :265-268
[3]   THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX FOR BENIGN PROSTATIC HYPERPLASIA [J].
BARRY, MJ ;
FOWLER, FJ ;
OLEARY, MP ;
BRUSKEWITZ, RC ;
HOLTGREWE, HL ;
MEBUST, WK ;
COCKETT, ATK ;
BLAIVAS, JG ;
WEIN, AJ .
JOURNAL OF UROLOGY, 1992, 148 (05) :1549-1557
[4]   Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone [J].
Behre, HM ;
Kliesch, S ;
Lemcke, B ;
von Eckardstein, S ;
Nieschlag, E .
HUMAN REPRODUCTION, 2001, 16 (12) :2570-2577
[5]  
BERGINK E, 1985, J STEROID BIOCHEM, V13, P259
[6]   Proof of the effect of testosterone on skeletal muscle [J].
Bhasin, S ;
Woodhouse, L ;
Storer, TW .
JOURNAL OF ENDOCRINOLOGY, 2001, 170 (01) :27-38
[7]   The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men [J].
Bhasin, S ;
Storer, TW ;
Berman, N ;
Callegari, C ;
Clevenger, B ;
Phillips, J ;
Bunnell, TJ ;
Tricker, R ;
Shirazi, A ;
Casaburi, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (01) :1-7
[8]   Testosterone replacement increases fat-free mass and muscle size in hypogonadal men [J].
Bhasin, S ;
Storer, TW ;
Berman, N ;
Yarasheski, KE ;
Clevenger, B ;
Phillips, J ;
Lee, WP ;
Bunnell, TJ ;
Casaburi, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :407-413
[9]   INFLUENCE OF TESTOSTERONE THERAPY ON CLINICAL AND IMMUNOLOGICAL FEATURES OF AUTOIMMUNE-DISEASES ASSOCIATED WITH KLINEFELTERS-SYNDROME [J].
BIZZARRO, A ;
VALENTINI, G ;
DIMARTINO, G ;
DAPONTE, A ;
DEBELLIS, A ;
IACONO, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1987, 64 (01) :32-36
[10]   Anabolic interventions for aging-associated sarcopenia [J].
Bross, R ;
Javanbakht, M ;
Bhasin, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (10) :3420-3430